Detail akcie Tevogen Bio Rg online

Business Summary: Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Tevogen Bio Holdings Inc revenues was not reported. Net loss applicable to common stockholders totaled $10.5M vs. income of $11.1M. Net loss reflects Change in fair value of convertible prom decrease from $48.5M (income) to $0K. Basic Earnings per Share excluding Extraordinary Items decreased from $0.07 to -$0.07.